Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)

NCT01797419 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

DRUG: GS-5806
DRUG: Placebo

Sponsor

Gilead Sciences